Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has provided an update.
CSL Limited has reported a change in the interests of non-executive director Cameron Bruce Price under its Non-Executive Director Rights Plan. The filing discloses that Price holds his interest indirectly via Solium Nominees (Australia) Pty Ltd acting as custodian, with additional ordinary shares held by his spouse.
Under the plan, Price acquired 263 rights, each convertible into one ordinary share, for a total consideration of about A$40,105 based on a volume-weighted average price. The rights were funded by contributing a portion of his board fees, reinforcing equity-based alignment between the director and shareholders without altering his direct holding, which remains nil.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$170.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company focused on developing and manufacturing vaccines, blood plasma-derived therapies and other biopharmaceutical products. The company serves healthcare systems and patients worldwide, with a particular focus on immunology, hematology, respiratory and transplant-related conditions, and maintains a significant presence in major developed markets.
YTD Price Performance: -10.69%
Average Trading Volume: 1,067,613
Technical Sentiment Signal: Sell
Current Market Cap: A$74.1B
For a thorough assessment of CSL stock, go to TipRanks’ Stock Analysis page.